ATNM

Actinium Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

1.260

-0.06(-4.545%)1D

Line

Candle

YTD

High

1.3195

Open

1.300

VWAP

1.26

Vol

286.60K

Mkt Cap

39.31M

Low

1.230

Amount

360.42K

EV/EBITDA(TTM)

Total Shares

29.78M

-20.61M

EV/OCF(TTM)

P/S(TTM)

Actinium Pharmaceuticals, Inc. specializes in the development of targeted radiotherapies. The Company is advancing its lead product candidate Actimab-A, a CD33 targeting therapeutic, as potential backbone therapy in acute myeloid leukemia (AML) and other myeloid malignancies leveraging the mutation agnostic alpha-emitter radioisotope payload Actinium-225 (Ac-225). The Company is engaged with the National Cancer Institute (NCI) under the Cooperative Research and Development Agreement (CRADA) for development of Actimab-A in AML and other myeloid malignancies. ATNM-400 is the Company's novel non-PSMA targeting Ac-225 radiotherapy for prostate cancer. Iomab-ACT, its conditioning candidate, is being developed to improve patient access and outcomes for potentially curative cell and gene therapies. Its Iomab-B program is an induction and conditioning agent prior to bone marrow transplant in patients with r/r AML, which it is seeking a potential strategic partner for the United States.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

-0.215

-57.84%

-0.204

-2.86%

-0.320

-13.51%

Estimates Revision

The market is revising No Change the revenue expectations for Actinium Pharmaceuticals, Inc. (ATNM) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -18.18%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-0.71%

In Past 3 Month

Stock Price

Go Down

-18.18%

In Past 3 Month

2 Analyst Rating

Wall Street analysts forecast ATNM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATNM is 4.50 USD with a low forecast of 4.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 1.260

Low

4.00

Averages

4.50

High

5.00

Current: 1.260

Low

4.00

Averages

4.50

High

5.00

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

2025-04-01

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

2025-04-01

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

2025-03-27

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

2025-03-27

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

2025-03-25

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

2025-03-25

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

2025-03-20

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

2025-03-20

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

2025-03-18

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

2025-03-18

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

2025-03-11

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

2025-03-11

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Actinium Pharmaceuticals Inc (ATNM.A) is -1.88, compared to its 5-year average forward P/E of -5.08. For a more detailed relative valuation and DCF analysis to assess Actinium Pharmaceuticals Inc 's fair value, click here.

Forward PE
Forward EV/EBITDA
Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.08

Current PE

-1.88

Overvalued PE

-2.26

Undervalued PE

-7.89

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.86

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

-0.24

Undervalued EV/EBITDA

-3.49

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

222.88

Current PS

1.26

Overvalued PS

662.29

Undervalued PS

-216.53

Financials

Annual

Quarterly

FY2025Q2

0.00

Total Revenue

FY2025Q2

YoY :

-39.58%

-7.50M

Operating Profit

FY2025Q2

YoY :

-39.42%

-6.88M

Net Income after Tax

FY2025Q2

YoY :

-42.11%

-0.22

EPS - Diluted

FY2025Q2

YoY :

-32.36%

-5.39M

Free Cash Flow

FY2025Q2

N/A

Gross Profit Margin - %

FY2025Q2

YoY :

-100.00%

N/A

FCF Margin - %

FY2025Q2

N/A

Net Margin - %

Trading Trends

Insider
Hedge Fund
Congress Trading

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

ATNM News & Events

Events Timeline

2025-10-27 (ET)

2025-10-27

07:12:59

Actinium Pharmaceuticals' ATNM-400 Demonstrates Enhanced Anti-Tumor Efficacy

2025-10-24 (ET)

2025-10-24

08:33:33

Actinium unveils preclinical findings for ATNM-400

2025-10-13 (ET)

2025-10-13

12:21:04

Actinium Pharmaceuticals to Reveal Preclinical Findings from ATNM-400 Program

News

9.0

11-04Newsfilter

Actinium Pharmaceuticals, Inc. to Showcase ATNM-400 Findings for Hormone-Resistant and HER2-Resistant Breast Cancer at the 2025 San Antonio Breast Cancer Symposium, Broadening Pan-Tumor Profile Across Three Solid Tumor Types

9.0

10-24Newsfilter

Actinium Pharmaceuticals Unveils New Findings Showcasing Strong and Lasting Effectiveness of ATNM-400, a Pioneering Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat

9.0

10-13Newsfilter

Actinium Pharmaceuticals to Present Data on ATNM-400, a Novel Actinium-225 Radiotherapy for Multiple Tumors, in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Treatments